Drugmaker AstraZeneca will cap out-of-pocket ... 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including ...

The approval in Europe was expected as in July, The Committee for Medicinal Products ... treat severe asthma with no phenotype limitation and irrespective of biomarker levels. AstraZeneca and ...

They're produced by an industry-leading manufacturer, but one U.S. agency warns of a defect concerning this well known ...

The Allergy & Asthma Network praised three major pharmaceutical companies, AstraZeneca, Boehringer Ingelheim and GSK, that announced they will enact a $35 price cap on their inhaler products.

Sanders noted AstraZeneca was selling its drug-device combination inhaler products for as much as $ ... for its portfolio of inhaler medicines for asthma and chronic obstructive pulmonary disease.

Asthma affects an estimated 262 million people globally ... The success of AIRSUPRA and other products in AstraZeneca's portfolio contributes to the company's strong profitability. With a gross profit ...

The China National Medical Products Association (NMPA ... "NMPA approves AstraZeneca’s Fasenra for severe asthma" was originally created and published by Pharmaceutical Technology, a GlobalData ...

These results could potentially change the standard of care for asthma ... recent news, AstraZeneca has reported several notable developments. The company received a recommendation from the European ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ... We sell different types of products and services to both ...

WILMINGTON, Del. - AstraZeneca (Market cap: $219.79B), a prominent player in the pharmaceuticals industry with an "GREAT" financial health rating according to InvestingPro, announced its triple ...